

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy

The ARCADIA Randomized Clinical Trial

Hooman Kamel, MD¹; W. T. Longstreth Jr, MD^{2,3,4}; David L. Tirschwell, MD²; Richard A. Kronmal, PhD⁵; Randolph S. Marshall, MD⁶; Joseph P. Broderick, MD⁷; Rebeca Aragón García, BS⁶; Pamela Plummer, MSN⁷; Noor Sabagha, RPH⁷; Qi Pauls, MS⁸; Christy Cassarly, PhD⁸; Catherine R. Dillon, MS⁸; Marco R. Di Tullio, MD⁹; Eldad A. Hod, MD¹⁰; Elsayed Z. Soliman, MD¹¹; David J. Gladstone, MD¹²; Jeff S. Healey, MD¹³; Mukul Sharma, MD¹³; Seemant Chaturvedi, MD¹⁴; L. Scott Janis, PhD¹⁵; Balaji Krishnaiah, MD¹⁶; Fadi Nahab, MD¹⁷; Scott E. Kasner, MD¹⁸; Robert J. Stanton, MD⁷; Dawn O. Kleindorfer, MD¹⁹; Matthew Starr, MD²⁰; Toni R. Winder, MD²¹; Wayne M. Clark, MD²²; Benjamin R. Miller, MD²³; Mitchell S. V. Elkind, MD^{6,24}; for the ARCADIA Investigators

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy

The ARCADIA Randomized Clinical Trial

Abstract

Importance Atrial cardiopathy is associated with stroke in the absence of clinically apparent atrial fibrillation. It is unknown whether anticoagulation, which has proven benefit in atrial fibrillation, prevents stroke in patients with atrial cardiopathy and no atrial fibrillation.

Objective To compare anticoagulation vs antiplatelet therapy for secondary stroke prevention in patients with cryptogenic stroke and evidence of atrial cardiopathy.

Design, Setting, and Participants Multicenter, double-blind, phase 3 randomized clinical trial of 1015 participants with cryptogenic stroke and evidence of atrial cardiopathy, defined as P-wave terminal force greater than 5000 $\mu\text{V} \times \text{ms}$ in electrocardiogram lead V₁, serum N-terminal pro-B-type natriuretic peptide level greater than 250 pg/mL, or left atrial diameter index of 3 cm/m² or greater on echocardiogram. Participants had no evidence of atrial fibrillation at the time of randomization. Enrollment and follow-up occurred from February 1, 2018, through February 28, 2023, at 185 sites in the National Institutes of Health StrokeNet and the Canadian Stroke Consortium.

Interventions Apixaban, 5 mg or 2.5 mg, twice daily (n=507) vs aspirin, 81 mg, once daily (n=508).

QUESTION Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke in patients with cryptogenic stroke and evidence of atrial cardiopathy?

CONCLUSION This randomized trial found that in patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not significantly reduce recurrent stroke risk compared with aspirin.

POPULATION

551 Women
464 Men



Adults ≥45 years with cryptogenic stroke and evidence of atrial cardiopathy

Mean age: 68 years

LOCATIONS

185 Sites in the US and Canada



INTERVENTION

1015 Patients randomized

507

Apixaban

Oral dose of apixaban, 5 mg or 2.5 mg, twice daily + aspirin placebo



508

Aspirin

Oral dose of aspirin, 81 mg, once daily + apixaban placebo



PRIMARY OUTCOME

Recurrent stroke of any type

FINDINGS

Recurrent stroke

Apixaban
Annualized rate, **4.4%**
(40 of 507 patients)

Aspirin
Annualized rate, **4.4%**
(40 of 508 patients)

Apixaban did not significantly reduce recurrent stroke risk vs aspirin.

Hazard ratio, **1.00**
(95% CI, 0.64 to 1.55)

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy

The ARCADIA Randomized Clinical Trial

Abstract

Main Outcomes and Measures The primary efficacy outcome in a time-to-event analysis was recurrent stroke. All participants, including those diagnosed with atrial fibrillation after randomization, were analyzed according to the groups to which they were randomized. The primary safety outcomes were symptomatic intracranial hemorrhage and other major hemorrhage.

Results With 1015 of the target 1100 participants enrolled and mean follow-up of 1.8 years, the trial was stopped for futility after a planned interim analysis. The mean (SD) age of participants was 68.0 (11.0) years, 54.3% were female, and 87.5% completed the full duration of follow-up. Recurrent stroke occurred in 40 patients in the apixaban group (annualized rate, 4.4%) and 40 patients in the aspirin group (annualized rate, 4.4%) (hazard ratio, 1.00 [95% CI, 0.64-1.55]). Symptomatic intracranial hemorrhage occurred in 0 patients taking apixaban and 7 patients taking aspirin (annualized rate, 1.1%). Other major hemorrhages occurred in 5 patients taking apixaban (annualized rate, 0.7%) and 5 patients taking aspirin (annualized rate, 0.8%) (hazard ratio, 1.02 [95% CI, 0.29-3.52]).

Conclusions and Relevance In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not significantly reduce recurrent stroke risk compared with aspirin.

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy

The ARCADIA Randomized Clinical Trial

Key Points

Question Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke in patients with cryptogenic stroke and evidence of atrial cardiopathy?

Findings In this randomized clinical trial that included 1015 patients, the rate of recurrent stroke did not significantly differ between the apixaban group (annualized rate, 4.4%) and the aspirin group (annualized rate, 4.4%).

Meaning In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not significantly reduce recurrent stroke risk compared with aspirin.

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy

The ARCADIA Randomized Clinical Trial

Editorial

It can be counterintuitive for patients with atrial fibrillation (AF) to understand the evidence-based recommendation to receive anticoagulation therapy despite successful suppression of their arrhythmia with an antiarrhythmic drug.¹ After all, the general teaching is that the heightened risk of stroke and systemic thromboemboli occurs due to the stasis of blood in the left atrial appendage produced during rapid and disorganized fibrillation of atrial tissue. And yet, randomized clinical trial data have shown that cessation of anticoagulation given maintenance of sinus rhythm may be harmful² and that the benefit of AF suppression can be achieved only when anticoagulation is maintained.³ How can this be? One potential explanation is that the AF is an epiphenomenon, serving as a marker of an underlying atrial myopathy, or atrial cardiopathy, and not necessarily causal.⁴ If true, this would suggest that the optimal selection of patients for anticoagulation might not rely solely on evidence of AF, but rather on other biomarkers of atria prone to forming thrombi.